[1] Ye Q, Zou B, Yeo YH, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol, 2020, 5(8):739-752. [2] Zou Y, Yu M, Sheng G. Association between fasting plasma glucose and nonalcoholic fatty liver disease in a nonobese Chinese population with normal blood lipid levels: a prospective cohort study. Lipids Health Dis, 2020, 19(1):145. [3] Xu S, Chen L, Hong D, et al. Mean arterial pressure is related to incident nonalcoholic fatty liver disease among the nonobese female with normal low-density lipoprotein cholesterol levels: a large cohort study in China. Gastroenterol Res Pract, 2020, 2020:3580840. [4] Gaiani S, Avogaro A, Bombonato GC, et al. Nonalcoholic fatty liver disease (NAFLD) in nonobese patients with diabetes: Prevalence and relationships with hemodynamic alterations detected with Doppler sonography. J Ultrasound, 2009, 12(1):1-5. [5] Kim SH, Park HY, Lee HS, et al. Association between non-alcoholic fatty liver disease and coronary calcification depending on sex and obesity. Sci Rep, 2020, 10(1):1025. [6] Sun DQ, Wu SJ, Liu WY, et al. Association of low-density lipoprotein cholesterol within the normal range and NAFLD in the non-obese Chinese population: a cross-sectional and longitudinal study. BMJ Open, 2016, 6(12):e013781. [7] Satkunasingham J, Nik HH, Fischer S, et al. Can negligible hepatic steatosis determined by magnetic resonance imaging-proton density fat fraction obviate the need for liver biopsy in potential liver donors?. Liver Transpl, 2018, 24(4):470-477. [8] 瞿欢佳, 王磊, 金沛桦, 等. 氢质子磁共振波谱在脂肪性肝病肝脏甘油三酯含量测定中的价值及其影响因素. 中华肝脏病杂志, 2017, 25(11): 858-863. [9] 徐亮, 钟燕, 苏淑婷, 等. 反应性氧化物、脂联素在慢性乙型肝炎病毒感染合并非酒精性脂肪性肝病中的研究. 中华肝脏病杂志, 2020, 28(3): 247-253. [10] Xu N, Xie Q, Li J, et al. Improvement in liver stiffness measurement for diagnosis of liver fibrosis in patients with concurrent chronic hepatitis B and nonalcoholic fatty liver disease. J Int Med Res, 2020, 48(2):300060520903667. [11] Lee SJ, Kim SU. Noninvasive monitoring of hepatic steatosis: controlled attenuation parameter and magnetic resonance imaging-proton density fat fraction in patients with nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol, 2019, 13(6):523-530. [12] 中华医学会肝病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南. 中华糖尿病杂志, 2010, 2(1): 15-19. [13] 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪肝专家委员会. 非酒精性脂肪性肝病防治指南(2018年版). 实用肝脏病杂志, 2018, 21(2):177-186. [14] Liao R, Fu YP, Wang T, et al. Metavir and FIB-4 scores are associated with patient prognosis after curative hepatectomy in hepatitis B virus-related hepatocellular carcinoma:a retrospective cohort study at two centers in China. Oncotarget, 2017, 8(1): 1774-1781. [15] Eshraghian A, Nikeghbalian S, Geramizadeh B, et al. Characterization of biopsy proven non-alcoholic fatty liver disease in healthy non-obese and lean population of living liver donors: The impact of uric acid. Clin Res Hepatol Gastroenterol, 2020, 44(4):572-578. [16] Gu J, Liu S, Du S, et al. Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease: a meta-analysis. Eur Radiol, 2019, 29(7):3564-3573. [17] Caussy C, Alquiraish MH, Nguyen P, et al. Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis. Hepatology, 2018, 67(4):1348-1359. |